RougeTx raised $58 million in a Series A to advance an oral, once-daily therapeutic candidate for hereditary hemorrhagic telangiectasia (HHT). The funding supports early clinical progression and manufacturing readiness, reflecting investor appetite for rare-disease drugs that aim to shift treatment away from infusion- or multi-dose regimens.